MedPath

Zoledronic acid

Generic Name
Zoledronic acid
Brand Names
Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
Drug Type
Small Molecule
Chemical Formula
C5H10N2O7P2
CAS Number
118072-93-8
Unique Ingredient Identifier
70HZ18PH24
Background

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
Associated Therapies
Bone Mineral Density
Clinical Trials
Related News

Novel Injectable Hydrogel Shows Promise in Rapidly Strengthening Osteoporotic Bones

Swiss researchers have developed a groundbreaking nanoparticle hydrogel that can be injected directly into weakened bones, showing significant improvements in bone density within weeks. When combined with Zoledronate, the treatment demonstrated up to 4.8-fold increase in local bone density in preclinical studies, offering new hope for rapid intervention in osteoporosis patients.

Infrequent Zoledronate Infusions Reduce Fracture Risk in Early Postmenopausal Women

• A new study reveals that infrequent intravenous infusions of zoledronate significantly reduce the risk of fractures in early postmenopausal women. • Women receiving two zoledronate infusions five years apart experienced a 44% reduction in spinal fractures compared to those receiving a placebo. • The research suggests that zoledronate, due to its generic availability and infrequent administration, offers a cost-effective strategy for early fracture prevention. • Findings indicate potential for primary fracture prevention in women with any bone mineral density, especially those concerned about future fracture risk.

Axsome's AXS-05 Shows Promise in Alzheimer's Agitation Trials, NDA Submission Planned for 2025

• Axsome Therapeutics' AXS-05 demonstrated a statistically significant delay in agitation relapse in Alzheimer's patients in the ACCORD-2 Phase 3 trial. • The ADVANCE-2 trial did not meet its primary endpoint, but results numerically favored AXS-05, with a good safety profile across trials. • Axsome plans to submit an NDA to the FDA in the second half of 2025, supported by data from four Phase 3 trials. • AXS-05 has Breakthrough Therapy designation, potentially expediting its review for Alzheimer's disease agitation, a condition with limited options.

Radium-223 Plus Enzalutamide Improves Survival in mCRPC with Bone Metastases

• The PEACE-3 trial demonstrated that adding Radium-223 to enzalutamide significantly improved radiographic progression-free survival (rPFS) in mCRPC patients with bone metastases. • The combination therapy also led to a statistically significant improvement in overall survival (OS) compared to enzalutamide alone, with a manageable safety profile. • Time to next systemic treatment was significantly prolonged with the combination, suggesting a potential new first-line treatment option. • The study mandated bone-protecting agents, highlighting their importance in managing bone health in patients receiving this combination therapy.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy